See the latest news and media coverage for Moberg Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Commercial-stage dermatology pharmaceutical company
mobergpharma.seLast updated
In short: Moberg Pharma expanded its MOB-015 partnership with Karo Healthcare to APAC and China while preparing for a broader European launch.
Net revenues increased to SEK 10.7 million, the loss decreased, and the first European countries approved the brand change, as well as license agreements were concluded for APAC and China.
Helena Jansson becomes Chief Business Officer and Vaidrius Navikas Chief Medical Officer. Christina Erixon leaves the management team but remains as a consultant.
The exclusive license agreement with Karo Healthcare covers Australia, New Zealand, South Korea, and Taiwan, complementing existing European markets.
The company issued 592,361 C-shares, repurchased and converted them into common shares, which increases the number to 48,712,067, intended for hedging incentive programs.
The pharmaceutical company Moberg Pharma reports a net loss of SEK 1.3 million for the first quarter of 2026 (loss of SEK 2.8 million). The result...
Moberg Pharma's operating result amounted to -7.5 million kronor for the fourth quarter of 2025 (-308). Sales amounted to 2.1 million kronor (1.0). The net result was -12.8 million...
Moberg Pharma AB ( (SE:MOB)) has provided an update. Moberg Pharma AB has announced a significant expansion into the European market through an exclusive license...
STOCKHOLM, Nov. 5, 2025 /PRNewswire/ -- Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of...
Track Moberg Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Moberg Pharma and other trending companies.